NVIDIA’s $96B Quarter Hides a Supply-Chain Warning

In Short

NVIDIA's $96B quarter (106% YoY) hides a supply crunch that's capping growth. Stock fell 1.6% after hours as guidance slows to 70%. Is the AI boom hitting physical limits? Read the full analysis to see what management isn't telling you.

The Lede and the Real Story

NVIDIA just reported a quarter that looks like a fantasy: revenue of $96.2 billion, up 106% year-over-year, with earnings per share of $2.09 beating estimates by 6 cents. The stock, however, fell 1.59% to $209.66 in after-hours trading—a classic ‘sell the news’ reaction that suggests the market sees something the headline numbers don’t. The real story isn’t the growth—it’s the supply constraint that management admits is the ‘main constraint’ on future revenue. CFO Colette Kress opened with a triumphant ‘record revenue, operating income, and EPS,’ but the tone shifted when analysts pressed on how long this can last. The tension: NVIDIA is selling every chip it can make, but it can’t make enough to meet demand, and the company’s guidance of 70% growth for next quarter—while still spectacular—is a deceleration from the triple-digit pace. Investors are left wondering: Is this a temporary bottleneck, or a sign that the AI boom is hitting physical limits?

Inside the Full Analysis

  • 🔒The Negative Space — What They Didn’t Say
  • 🔒Script vs. Reality
  • 🔒Evasion Tactics & The Hot Seat
  • 🔒Excuses vs. Execution
  • 🔒The CAN SLIM Check
  • 🔒Conclusion


Discover more from CANSLIM Research

Subscribe to get the latest posts sent to your email.

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.

Discover more from CANSLIM Research

Subscribe now to keep reading and get access to the full archive.

Continue reading